| HOME >> MEDICINE >> TECHNOLOGY |
Revenue from Endu, the Company's patented anti-cancer biotech product, amounted to RMB67.9 million (US$10.3 million) in the fourth quarter of 2010, which was 11.6% of the Company's product revenue for the fourth quarter of 2010, an increase of 99.7% from RMB34.0 million for the same period in 2009. For the full year of 2010, revenue from Endu totaled RMB223.1 million (US$33.8 million), an increase of 79.6% from RMB124.2 million for the full year of 2009.
Revenue from Sinofuan, a 5-FU sustained release implant for the treatment of cancer, amounted to RMB36.1 million (US$5.5 million) for the fourth quarter of 2010, which was 6.1% of the Company's product revenue for the fourth quarter of 2010, an increase of 17.9% from RMB30.6 million for the same period in 2009. For the full year of 2010, revenue from Sinofuan totaled RMB151.8 million (US$23.0 million), an increase of 20.2% from RMB126.3 million for the full year of 2009.
Revenue from other branded generic products including Zailin and Yingtaiqingamounted to RMB255.4 million (US$38.7 million), which was 43.5% of the Company's product revenue for the fourth quarter of 2010, an increase of 20.4% from RMB212.1 million for the same period in 2009. For the full year of 2010, revenue from other branded generic products totaled RMB896.3 million (US$135.8 million), which represented an increase of 13.3% from RMB791.0 million for the full year of 2009.
Gross margin for the fourth quarter of 2010 was 84.1%, increasing from 83.6% for the same period in 2009. For the full year of 2010, gross margin was 84.0%, increasing from 82.7% for the full year of 2009.
Research and development expenses for the fourth quarter of 2010 totaled RMB31.4 million (US$4.8 million), which represented a decrease of 37.3
'/>"/>
| SOURCE Simcere Pharmaceutical Group Copyright©2010 PR Newswire. All rights reserved |